MA54227A - Méthodes de traitement de la fibrose kystique - Google Patents

Méthodes de traitement de la fibrose kystique

Info

Publication number
MA54227A
MA54227A MA054227A MA54227A MA54227A MA 54227 A MA54227 A MA 54227A MA 054227 A MA054227 A MA 054227A MA 54227 A MA54227 A MA 54227A MA 54227 A MA54227 A MA 54227A
Authority
MA
Morocco
Prior art keywords
cystic fibrosis
treatment methods
fibrosis treatment
cystic
methods
Prior art date
Application number
MA054227A
Other languages
English (en)
Other versions
MA54227B1 (fr
Inventor
David M Altshuler
Corey Don Anderson
Bartlomiej Borek
Weichao George Chen
Jeremy J Clemens
Thomas Cleveland
Timothy Richard Coon
Bryan Frieman
Peter Grootenhuis (Deceased)
Ruah Sara Sabina Hadida
Brian J Hare
Reshma Kewalramani
Jason Mccartney
Mark Thomas Miller
Prasuna Paraselli
Fabrice Pierre
Sarah M Robertson
Patrick R Sosnay
Sara E Swift
Goor Fredrick Van
Tim Young
Jinglan Zhou
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68808572&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA54227(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of MA54227A publication Critical patent/MA54227A/fr
Publication of MA54227B1 publication Critical patent/MA54227B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
MA54227A 2018-11-14 2019-11-13 Méthodes de traitement de la fibrose kystique MA54227B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862767202P 2018-11-14 2018-11-14
PCT/US2019/061171 WO2020102346A1 (fr) 2018-11-14 2019-11-13 Méthodes de traitement de la fibrose kystique

Publications (2)

Publication Number Publication Date
MA54227A true MA54227A (fr) 2021-09-22
MA54227B1 MA54227B1 (fr) 2023-03-31

Family

ID=68808572

Family Applications (1)

Application Number Title Priority Date Filing Date
MA54227A MA54227B1 (fr) 2018-11-14 2019-11-13 Méthodes de traitement de la fibrose kystique

Country Status (22)

Country Link
US (1) US20220047564A1 (fr)
EP (2) EP4218754A3 (fr)
AU (1) AU2019381750A1 (fr)
BR (1) BR112021009145A2 (fr)
CA (1) CA3123578A1 (fr)
CL (1) CL2021001248A1 (fr)
CO (1) CO2021007447A2 (fr)
DK (1) DK3880197T3 (fr)
EA (1) EA202191361A1 (fr)
ES (1) ES2943126T3 (fr)
FI (1) FI3880197T3 (fr)
HR (1) HRP20230272T1 (fr)
HU (1) HUE061686T2 (fr)
IL (1) IL282988A (fr)
LT (1) LT3880197T (fr)
MA (1) MA54227B1 (fr)
MD (1) MD3880197T2 (fr)
PL (1) PL3880197T3 (fr)
PT (1) PT3880197T (fr)
RS (1) RS64192B1 (fr)
SI (1) SI3880197T1 (fr)
WO (1) WO2020102346A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202004264VA (en) * 2017-12-01 2020-06-29 Vertex Pharma Processes for making modulators of cystic fibrosis transmembrane conductance regulator
PT3752510T (pt) 2018-02-15 2023-03-15 Vertex Pharma Macrociclos como moduladores do regulador de condutância de transmembrana da fibrose cística, suas composições farmacêuticas, seu uso no tratamento da fibrose cística e processos para produzi-los
WO2021030552A1 (fr) 2019-08-14 2021-02-18 Vertex Pharmaceuticals Incorporated Formes cristallines de modulateurs de cftr
TW202115092A (zh) 2019-08-14 2021-04-16 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白之調節劑
TW202120517A (zh) 2019-08-14 2021-06-01 美商維泰克斯製藥公司 製備cftr調節劑之方法
EP4259139A1 (fr) 2020-12-10 2023-10-18 Vertex Pharmaceuticals Incorporated Méthodes de traitement de la mucoviscidose
TW202333699A (zh) 2022-02-03 2023-09-01 美商維泰克斯製藥公司 囊腫纖維化之治療方法
WO2023150236A1 (fr) 2022-02-03 2023-08-10 Vertex Pharmaceuticals Incorporated Procédés de préparation et formes cristallines de (6a,12a)-17-amino-12-méthyl-6,15-bis(trifluorométhyl)-13,19-dioxa-3,4,18-triazatricyclo[ 12.3.1.12,5]nonadéca-1(18),2,4,14,16-pentaén-6-ol
WO2023154291A1 (fr) 2022-02-08 2023-08-17 Vertex Pharmaceuticals Incorporated Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique
WO2023224931A1 (fr) 2022-05-16 2023-11-23 Vertex Pharmaceuticals Incorporated Méthodes de traitement de la fibrose kystique
WO2023224924A1 (fr) 2022-05-16 2023-11-23 Vertex Pharmaceuticals Incorporated Formes solides de composés macrocycliques en tant que modulateurs de cftr et leur préparation

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
CA2672549A1 (fr) 2001-11-14 2003-06-12 Ben-Zion Dolitzky Formes cristallines amorphes de losartan potassique et leur procede de preparation
CA2652072A1 (fr) 2006-05-12 2007-11-22 Vertex Pharmaceuticals Incorporated Compositions de n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoleine-3-carboxamide
ES2857152T3 (es) 2008-08-13 2021-09-28 Vertex Pharma Composición farmacéutica y administraciones de la misma
MX2011003249A (es) 2008-09-29 2011-05-19 Vertex Pharma Unidades de dosificacion del acido 3-(6-(1-(2,2-difluorobenzo[d][1 ,3]dioxol-5-il)ciclopropancarboxamido)-3-metilpiridin-2-il)benzoi co.
RU2711481C2 (ru) 2010-03-25 2020-01-17 Вертекс Фармасьютикалз Инкорпорейтед ТВЕРДЫЕ ФОРМЫ (R)-1-(2, 2-ДИФТОРБЕНЗО[d][1, 3]ДИОКСОЛ-5-ИЛ)-N-(1-(2, 3-ДИГИДРОКСИПРОПИЛ)-6-ФТОР-2-(1-ГИДРОКСИ-2-МЕТИЛПРОПАН-2-ИЛ)-1H-ИНДОЛ-5-ИЛ)ЦИКЛОПРОПАНКАРБОКСАМИДА
JP2013523833A (ja) 2010-04-07 2013-06-17 バーテックス ファーマシューティカルズ インコーポレイテッド ３−（６−（１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）シクロプロパンカルボキサミド）−３−メチルピリジン−２−イル）安息香酸の医薬組成物およびその投与
CA2796642A1 (fr) 2010-04-22 2011-10-27 Vertex Pharmaceuticals Incorporated Compositions pharmaceutiques et leurs administrations
CA2797118C (fr) 2010-04-22 2021-03-30 Vertex Pharmaceuticals Incorporated Procede de production de composes de cycloalkylcarboxamido-indole
RU2013113627A (ru) 2010-08-27 2014-10-10 Вертекс Фармасьютикалз Инкорпорейтед Фармацевтическая композиция и ее введения
HUE047354T2 (hu) 2011-05-18 2020-04-28 Vertex Pharmaceuticals Europe Ltd Ivacaftor deuterizált származékai
CN109966264A (zh) 2012-02-27 2019-07-05 沃泰克斯药物股份有限公司 药物组合物及其施用
EP2872122A1 (fr) 2012-07-16 2015-05-20 Vertex Pharmaceuticals Incorporated Compositions pharmaceutiques de (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide et son administration
SG10201703452PA (en) 2012-11-02 2017-06-29 Vertex Pharma Pharmaceutical compositions for the treatment of cftr mediated diseases
KR102447581B1 (ko) 2014-04-15 2022-09-28 버텍스 파마슈티칼스 인코포레이티드 낭포성 섬유증 막전도 조절자 매개 질환 치료용 약제학적 조성물
PL3203840T3 (pl) 2014-10-06 2021-01-11 Vertex Pharmaceuticals Incorporated Modulatory mukowiscydozowego przezbłonowego regulatora przewodnictwa
BR112018005454A2 (pt) 2015-09-21 2018-10-09 Vertex Pharmaceuticals Europe Ltd administração de potencializadores de cftr deuterados
WO2018064632A1 (fr) 2016-09-30 2018-04-05 Vertex Pharmaceuticals Incorporated Modulateur de régulateur de conductance transmembranaire de fibrose kystique, compositions pharmaceutiques, procédés de traitement et procédé de fabrication du modulateur
AU2017352206B2 (en) 2016-10-27 2022-03-03 Vertex Pharmaceuticals (Europe) Limited Methods of treatment with deuterated CFTR potentiators
CA3069225A1 (fr) * 2017-07-17 2019-01-24 Vertex Pharmaceuticals Incorporated Methodes de traitement de la fibrose kystique
AU2018304168B2 (en) * 2017-07-17 2023-05-04 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
TWI810243B (zh) * 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
PT3752510T (pt) * 2018-02-15 2023-03-15 Vertex Pharma Macrociclos como moduladores do regulador de condutância de transmembrana da fibrose cística, suas composições farmacêuticas, seu uso no tratamento da fibrose cística e processos para produzi-los

Also Published As

Publication number Publication date
PL3880197T3 (pl) 2023-07-31
CO2021007447A2 (es) 2021-12-10
RS64192B1 (sr) 2023-06-30
AU2019381750A1 (en) 2021-06-24
BR112021009145A2 (pt) 2021-08-10
EP4218754A3 (fr) 2023-08-16
IL282988A (en) 2021-06-30
MD3880197T2 (ro) 2023-08-31
ES2943126T3 (es) 2023-06-09
US20220047564A1 (en) 2022-02-17
EA202191361A1 (ru) 2021-08-11
EP3880197A1 (fr) 2021-09-22
MA54227B1 (fr) 2023-03-31
LT3880197T (lt) 2023-05-10
WO2020102346A1 (fr) 2020-05-22
HRP20230272T1 (hr) 2023-04-28
HUE061686T2 (hu) 2023-08-28
SI3880197T1 (sl) 2023-04-28
FI3880197T3 (fi) 2023-05-04
EP4218754A2 (fr) 2023-08-02
PT3880197T (pt) 2023-05-09
EP3880197B1 (fr) 2023-02-22
DK3880197T3 (da) 2023-03-27
CA3123578A1 (fr) 2020-05-20
CL2021001248A1 (es) 2021-11-26

Similar Documents

Publication Publication Date Title
MA49631A (fr) Méthodes de traitement de la fibrose kystique
MA54105A (fr) Méthodes de traitement de la fibrose kystique
MA54227A (fr) Méthodes de traitement de la fibrose kystique
DK3706796T3 (da) Eksosomerer som RNA terapeutikske midler
MA47558A (fr) Traitement de la fibrose
MA46102A (fr) Composés de tétracycline et méthodes de traitement
MA39748A (fr) Cenicriviroc pour le traitement de la fibrose
CL2020000173S1 (es) Masajeador.
MA48996A (fr) Méthodes de traitement de maladies neurodégénératives
MA53882A (fr) Méthodes de traitement de la sclérose en plaques
DK3784103T3 (da) Gulvbehandlingsmaskine
BR112017014213A2 (pt) moduladores de ciclopropanocarboxamida do regulador da condutância transmembrana da fibrose cística.
FR3039368B1 (fr) Procede de traitement cosmetique
MA54860A (fr) Méthodes de traitement du myélome multiple
MA51678A (fr) Méthodes de traitement de l'amyotrophie musculaire
BR112017011897A2 (pt) métodos de tratamento da fibrose
TWI800561B (zh) 毛髮處理方法
MA52738A (fr) Méthodes de traitement de l'arthrite psoriasique
MA48625A (fr) Composés et méthodes de traitement de la douleur viscérale
MA53602A (fr) Méthodes de traitement du psoriasis
BR112016025080A2 (pt) método de tratamento de fibrose pulmonar idiopática.
FR3030270B1 (fr) Procede de traitement cosmetique et kit associe
MA50914A (fr) Vecteurs viraux comprenant des séquences codantes de rdh12 et méthodes de traitement de dystrophies rétiniennes
ES1215799Y (es) Dispositivo de masaje cardiaco
UA41274S (uk) Масажер